Neuroprotective Effects of Metformin Through the Modulation of Neuroinflammation and Oxidative Stress.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical and clinical mechanistic literature without systematic search methodology
PubMed 40710317 · doi:10.3390/cells14141064
What was done
This narrative review synthesized preclinical and clinical literature to describe the mechanisms through which the antidiabetic drug metformin exerts neuroprotective effects in neurodegenerative disorders, type 2 diabetes-related cognitive decline, stroke, and aging.
What was found
The abstract reports no numerical data or effect sizes. Metformin is described as reducing neuroinflammation by inhibiting microglial activation and suppressing proinflammatory cytokines, combating oxidative stress by triggering the Nrf2 pathway, strengthening blood-brain barrier integrity, and increasing autophagic flux.
Why it matters
Metformin represents an accessible therapeutic agent that may offer multi-target neuroprotection beyond glycemic control, particularly for Alzheimer's disease and diabetes-associated cognitive impairment.
Limits
The abstract provides no sample sizes, study counts, or quantitative metrics. As a narrative review relying heavily on mechanistic and preclinical findings, it cannot establish clinical efficacy, and the reported benefits vary across populations and underlying conditions.
Cited by
- supports Metformin crosses the blood-brain barrier, supports the TCA cycle in mitochondria, and reduces inflammatory cytokines such as TNF-alpha and interleukin-6 in studies.